A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

NCT07687602 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
69
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie